Handelsbanken Fonder’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Handelsbanken Fonder’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-21,500	Closed	-$79K	–	1576
2024 Q3	$79K	Hold	21,500	–	–	﹤0.01%	1516
2024 Q2	$88K	Buy	21,500 +8,000	+59%	+$89.3K	﹤0.01%	1514
2024 Q1	$213K	Hold	13,500	–	–	﹤0.01%	1499
2023 Q4	$205K	Buy	+13,500	New	+$197K	﹤0.01%	1507
2023 Q3	–	Sell	-8,300	Closed	-$234K	–	1582
2023 Q2	$234K	Buy	+8,300	New	+$199K	﹤0.01%	1449
2022 Q2	–	Sell	-6,900	Closed	-$318K	–	1702
2022 Q1	$318K	Sell	6,900 -2,000	-22%	-$108K	﹤0.01%	1487
2021 Q4	$748K	Sell	8,900 -800	-8%	-$61.9K	﹤0.01%	1073
2021 Q3	$646K	Hold	9,700	–	–	﹤0.01%	1182
2021 Q2	$516K	Buy	+9,700	New	+$520K	﹤0.01%	1359

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Handelsbanken Fonder's ZNTL Position: Q4 2024 in Review

Handelsbanken Fonder sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2024, closing a stake of 21,500 shares — an estimated $79K sold.

Handelsbanken Fonder first reported a position in ZNTL in Q2 2021 and held it in 9 quarters. The position peaked at $748K in Q4 2021. 142 funds tracked by Wall St. Rank hold ZNTL as of Q4 2024.

Handelsbanken Fonder reported no remaining Zentalis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Handelsbanken Fonder sold 21,500 Zentalis Pharmaceuticals shares in Q4 2024, an estimated $79K.
Handelsbanken Fonder first reported a position in Zentalis Pharmaceuticals in Q2 2021 and held it in 9 quarters.
Handelsbanken Fonder's Zentalis Pharmaceuticals position peaked at $748K in Q4 2021.
142 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2024.

Based on Handelsbanken Fonder's 13F filing for Q4 2024, filed 3 Feb 2025.